BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 16899591)

  • 1. The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients.
    Yaal-Hahoshen N; Shina S; Leider-Trejo L; Barnea I; Shabtai EL; Azenshtein E; Greenberg I; Keydar I; Ben-Baruch A
    Clin Cancer Res; 2006 Aug; 12(15):4474-80. PubMed ID: 16899591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
    Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
    Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer.
    Kawai H; Ishii A; Washiya K; Konno T; Kon H; Yamaya C; Ono I; Minamiya Y; Ogawa J
    Clin Cancer Res; 2005 Jul; 11(14):5084-9. PubMed ID: 16033821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LEA.135 expression: its comparison with other prognostic biomarkers for patients with primary breast carcinoma.
    Liu D; Baltayan A; Naritoku WY; Barr NJ; Young LL; Chaiwun B; Tsao-Wei DD; Groshen SL; Taylor CR; Torloni H; Neville AM; Cote RJ; Imam SA
    Anticancer Res; 2000; 20(3A):1451-61. PubMed ID: 10928056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
    Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer.
    Oduwole OO; Li Y; Isomaa VV; Mäntyniemi A; Pulkka AE; Soini Y; Vihko PT
    Cancer Res; 2004 Oct; 64(20):7604-9. PubMed ID: 15492288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression of ER beta protein correlates with vascular endothelial growth factor and its prognostic significance in human breast cancer.
    Wen XF; Shen Z; Shen ZZ; Nguyen M; Shao ZM
    Oncol Rep; 2002; 9(5):937-44. PubMed ID: 12168051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased expression of osteopontin in patients with triple-negative breast cancer.
    Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
    Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer.
    Rody A; Karn T; Ruckhäberle E; Müller V; Gehrmann M; Solbach C; Ahr A; Gätje R; Holtrich U; Kaufmann M
    Breast Cancer Res Treat; 2009 Feb; 113(3):457-66. PubMed ID: 18340528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
    Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
    APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis.
    Wu K; Quan Z; Weng Z; Li F; Zhang Y; Yao X; Chen Y; Budman D; Goldberg ID; Shi YE
    Breast Cancer Res Treat; 2007 Mar; 101(3):259-67. PubMed ID: 16821081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multimarker model to predict outcome in tamoxifen-treated breast cancer patients.
    Linke SP; Bremer TM; Herold CD; Sauter G; Diamond C
    Clin Cancer Res; 2006 Feb; 12(4):1175-83. PubMed ID: 16489071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
    Sharif MA; Mamoon N; Mushtaq S; Khadim MT
    J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The importance of prognostic factors in premenopausal women with breast cancer.
    Finek J; Holubec L; Topolcan O; Elgrova L; Skalova A; Pecen L
    Anticancer Res; 2007; 27(4A):1893-6. PubMed ID: 17649790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progesterone receptor expression is a marker for early stage breast cancer: implications for progesterone receptor as a therapeutic tool and target.
    Coyle YM; Xie XJ; Hardy DB; Ashfaq R; Mendelson CR
    Cancer Lett; 2007 Dec; 258(2):253-61. PubMed ID: 17950525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.